Combined estrogen and ghrelin administration decreases expression of p27(kip1) and proportion of isomyosin type I in the striated urethral and anal sphincters and levator ani of old ovariectomized rats.
We compared estrogen and/or ghrelin effects on pelvic floor muscles in old versus young adult ovariectomized rats. Ovariectomized Fisher 344 rats (18 and 3 months old, n = 24 x 2) received 42 daily intraperitoneal 17-beta estradiol (10 microg kg(-1)), ghrelin (2 microg kg(-1)), both, or vehicle (n = 6 x 4/group). Cytoplasmic p27(kip1) expression and isomyosin I proportion in striated urethral and anal sphincters and levator ani were measured, respectively, by Western blot analysis and gel electrophoresis with immunohistochemistry of muscle ghrelin receptors and radioimmunoassay of circulating growth hormone. In young adult rats, estrogen significantly decreased cytoplasmic p27(kip1) and isomyosin I signal intensities. In old rats, ghrelin and estrogen/ghrelin significantly decreased both intensities with greater estrogen/ghrelin effect. Ghrelin receptors were not immunostained in any muscle. Estrogen and/or ghrelin significantly increased or decreased, respectively, circulating growth hormone in old and young adult rats. Estrogen/ghrelin administration reversed pelvic floor muscle ageing changes in old ovariectomized rats through growth hormone production.
Rizk
Diaa E E
DE
Department of Obstetrics and Gynecology, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates. rizk.diaa@gmail.com
Hassan
Hazem A
HA
Al-Marzouqi
Ahmed H
AH
Shafiullah
Mohammed
M
Fahim
Mohamed A
MA
D001003:Anal Canal / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D000818:Animals; D015153:Blotting, Western; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000096:biosynthesis* / Q000187:drug effects; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000008:administration & dosage*; D004967:Estrogens / Q000008:administration & dosage; D005242:Fecal Incontinence / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D054439:Ghrelin / Q000008:administration & dosage*; D007150:Immunohistochemistry; D007274:Injections, Intraperitoneal; D009119:Muscle Contraction / Q000187:drug effects; D024461:Myosin Type I / Q000096:biosynthesis*; D010052:Ovariectomy / Q000009:adverse effects; D051381:Rats; D011916:Rats, Inbred F344; D014521:Urethra / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D014549:Urinary Incontinence / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology
D004967:Estrogens; D054439:Ghrelin; D050760:Cyclin-Dependent Kinase Inhibitor p27; D004958:Estradiol; D024461:Myosin Type I